Abstract
Specialized microfold cells (M cells) within the follicle-associated endothelium of intestinal Peyer’s patches play a key role in body’s defence mechanism by endocytosing macromolecules. Particulate uptake by the Peyer’s patch offers a very attractive avenue for delivering drugs through the peroral route. This review describes the pathway of drug delivery by Peyer’s patch targeting and its associated advantages. Disorders affecting the function of the lymphatic and immune system can be treated by targeting the active moieties at the Peyer’s patch. Drugs have been delivered to the Peyer’s patch for autoimmune disorders like HIV/AIDS, rheumatoid arthritis, chronic inflammatory disorders, tuberculosis, psoriasis and cancer. Several drug delivery systems like nanoparticles, dendrimers, microspheres, SMEDDS and liposomes have been reviewed for oral lymphatic delivery of small-sized drugs as well as macromolecular drugs like vaccines for immunogenic response. Factors such as surface charge, size, hydrophobicity, surface modification and conjugation have been found to be important determinants in modulating the targeting of these drugs to Peyer’s patches. These novel drug carriers are particularly useful in improving the oral bioavailability and efficacy of the drugs by selective utilization of lymphatic absorption avoiding the portal circulation. Further research in the direction of elucidating the mechanisms of drug transport to the intestinal lymphatic system specifically the cellular and intracellular events may help in delivering a greater number of drugs through the Peyer’s patch.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Florence AT, Hillery AM, Hussain N, Jani PU (1995) Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Control Release 36(1–2):39–46
Koteswari P, Devia KV, Nagabhushanama MV, Nazmaa S (2017) A systematic review on advanced drug delivery technologies to target the lymphatic systems. Int J Pharm Sci Rev Res 43(1):7–11
Brayden DJ, Jepson MA, Baird AW (2005) Keynote review: intestinal Peyer’s patch M cells and oral vaccine targeting. Drug Discov Today 10(17):1145–1157
Azizi A, Kumar A, Diaz-Mitoma F, Mestecky J (2010) Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog 6(11):e1001147
Managuli RS, Raut SY, Reddy MS, Mutalik SJ (2018) Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs. Expert Opin Drug Deliv 15(8):787–804
Garinot M, Fiévez V, Pourcelle V, Stoffelbach F, des Rieux A, Plapied L et al (2007) PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release 120(3):195–204
Shakweh M, Ponchel G, Fattal E (2004) Particle uptake by Peyer’s patches: a pathway for drug and vaccine delivery. Expert Opin Drug Deliv 1(1):141–163
Nelson AG, Zhang X, Ganapathi U, Szekely Z, Flexner CW, Owen A et al (2015) Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. J Control Release 219:669–680
Lackner AA, Mohan M, Veazey RS (2009) The gastrointestinal tract and AIDS pathogenesis. Gastroenterology 136(6):1966–1978
Min SY, Park KS, Cho ML, Kang JW, Cho YG, Hwang SY et al (2006) Antigen-induced, tolerogenic CD11c+, CD11b+ dendritic cells are abundant in Peyer’s patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum 54(3):887–898
Zhou J, Xiao C, Zhao L, Jia H, Zhao N, Lu C et al (2006) The effect of triptolide on CD4+ and CD8+ cells in Peyer’s patch of SD rats with collagen induced arthritis. Int Immunopharmacol 6(2):198–203
Hosoda T, Mito N, Yoshino H, Sato K (2004) Estrogen altered oral tolerance induction in type II collagen-induced murine arthritis. Int Arch Allergy Immunol 133(1):19–28
Kapur S, Watson W, Carr S (2018) Atopic dermatitis. Allergy Asthma Clin Immunol 14(Suppl 2):52
Lugton I (1999) Mucosa-associated lymphoid tissues as sites for uptake, carriage and excretion of tubercle bacilli and other pathogenic mycobacteria. Immunol Cell Biol 77(4):364–372
Coppi G, Iannuccelli V (2009) Alginate/chitosan microparticles for tamoxifen delivery to the lymphatic system. Int J Pharm 367(1–2):127–132
Bachhav SS, Dighe VD, Kotak D, Devarajan PV (2017) Rifampicin Lipid-Polymer hybrid nanoparticles (LIPOMER) for enhanced Peyer’s patch uptake. Int J Pharm 532(1):612–622
Prajapati JB, Katariya H, Patel R (2018) Peyer’s patch targeting of Isradipine loaded solid lipid nanoparticles: it’s cellular uptake study. J Drug Deliv Sci Technol 43:318–326
Shah U, Joshi G, Sawant K (2014) Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design. Mater Sci Eng C 35:153–163
Prajapati JB, Verma SD, Patel AA (2018) Oral bioavailability enhancement of agomelatine by loading into nanostructured lipid carriers: peyer’s patch targeting approach. Int J Nanomedicine 13:35
Shi L-L, Xie H, Lu J, Cao Y, Liu J-Y, Zhang X-X et al (2016) Positively charged surface-modified solid lipid nanoparticles promote the intestinal transport of docetaxel through multifunctional mechanisms in rats. Mol Pharm 13(8):2667–2676
Su C-W, Chiang M-Y, Lin Y-L, Tsai N-M, Chen Y-P, Li W-M et al (2016) Sodium dodecyl sulfate-modified doxorubicin-loaded chitosan-lipid nanocarrier with multi polysaccharide-lecithin nanoarchitecture for augmented bioavailability and stability of oral administration in vitro and in vivo. J Biomed Nanotechnol 12(5):962–972
Parayath NN, Nehoff H, Müller P, Taurin S, Greish K (2015) Styrene maleic acid micelles as a nanocarrier system for oral anticancer drug delivery–dual uptake through enterocytes and M-cells. Int J Nanomedicine 10:4653
Singh G, Pai RS (2014) Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential. Expert Opin Drug Deliv 11(5):647–659
Wong CY, Al-Salami H, Dass CR (2017) Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment. J Control Release 264:247–275
Nair AB, Kaushik A, Attimarad M, Al-Dhubiab BE (2012) Enhanced oral bioavailability of calcium using bovine serum albumin microspheres. Drug Deliv 19(6):277–285
Joshi G, Kumar A, Sawant K (2016) Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles. Drug Deliv 23(9):3492–3504
Singh G, Pai RS (2016) Atazanavir-loaded Eudragit RL 100 nanoparticles to improve oral bioavailability: optimization and in vitro/in vivo appraisal. Drug Deliv 23(2):532–539
Shukla A, Mishra V, Bhoop BS, Katare OP (2015) Alginate coated chitosan microparticles mediated oral delivery of diphtheria toxoid.(Part A). Systematic optimization, development and characterization. Int J Pharm 495(1):220–233
Kaur M, Malik B, Garg T, Rath G, Goyal AK (2015) Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis. Drug Deliv 22(3):328–334
Yeboah KG, Akande J, Addo RT, Siwale RC, Aninkorah-Yeboah K, Siddig A (2014) In vitro and ex vivo characterization of lectin-labelled Mycobacterium tuberculosis antigen-containing microspheres for enhanced oral delivery. J Drug Target 22(1):34–47
Liu Z, Lv D, Liu S, Gong J, Wang D, Xiong M et al (2013) Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in mice. PLoS One 8(4):e60190
Tawde SA, Chablani L, Akalkotkar A, D’Souza C, Chiriva-Internati M, Selvaraj P et al (2012) Formulation and evaluation of oral microparticulate ovarian cancer vaccines. Vaccine 30(38):5675–5681
Akalkotkar A, Tawde SA, Chablani L, D’Souza MJ (2012) Oral delivery of particulate prostate cancer vaccine: in vitro and in vivo evaluation. J Drug Target 20(4):338–346
D’Souza B, Bhowmik T, Shashidharamurthy R, Oettinger C, Selvaraj P, D’Souza M (2012) Oral microparticulate vaccine for melanoma using M-cell targeting. J Drug Target 20(2):166–173
Xiang R, Mizutani N, Luo Y, Chiodoni C, Zhou H, Mizutani M et al (2005) A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 65(2):553–561
Banerjee A, Qi J, Gogoi R, Wong J, Mitragotri S (2016) Role of nanoparticle size, shape and surface chemistry in oral drug delivery. J Control Release 238:176–185
Iannuccelli V, Montanari M, Bertelli D, Pellati F, Coppi G (2011) Microparticulate polyelectrolyte complexes for gentamicin transport across intestinal epithelia. Drug Deliv 18(1):26–37
Huang X, Xiao Y, Lang M (2012) Micelles/sodium-alginate composite gel beads: a new matrix for oral drug delivery of indomethacin. Carbohydr Polym 87(1):790–798
Momin M, Pundarikakshudu K, Nagori S (2008) Design and development of mixed film of pectin: ethyl cellulose for colon specific drug delivery of sennosides and triphala. Indian J Pharm Sci 70(3):338
Kalgaonkar S, Lönnerdal B (2009) Receptor-mediated uptake of ferritin-bound iron by human intestinal Caco-2 cells. J Nutr Biochem 20(4):304–311
Seifert J, Sass W (1990) Intestinal absorption of macromolecules and small particles. Dig Dis 8(3):169–178
Sass W, Dreyer H-P, Seifert JJAJoG (1990) Rapid insorption of small particles in the gut. Am J Gastroenterol 85(3):255–260
Seifert J, Haraszti B, Sass W (1996) The influence of age and particle number on absorption of polystyrene particles from the rat gut. J Anat 189(Pt 3):483
Gebert A, Rothkötter H-J, Pabst R (1996) M cells in Peyer’s patches of the intestine. Int Rev Cytol Elsevier 167:91–159
Beier R, Gebert A (1998) Kinetics of particle uptake in the domes of Peyer’s patches. Am J Physiol Gastrointest Liver Physiol 275(1):G130–G1G7
Böckmann J, Lahl H, Eckert T, Unterhalt B (2000) Blood titanium levels before and after oral administration titanium dioxide. Pharmazie 55(2):140–143
Volkheimer G (1974) Passage of particles through the wall of the gastrointestinal tract. Environ Health Perspect 9:215
Volkheimer G (1993) Persorption of microparticles. Pathologe 14(5):247e52
Powell J, Whitehead M, Lee S, Thompson R (1994) Mechanisms of gastrointestinal absorption: dietary minerals and the influence of beverage ingestion. Food Chem 51(4):381–388
Powell JJ, Faria N, Thomas-McKay E, Pele LC (2010) Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 34(3):J226–JJ33
des Rieux A, Ragnarsson EG, Gullberg E, Préat V, Schneider Y-J, Artursson P (2005) Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur J Pharm Sci 25(4–5):455–465
Desai MP, Labhasetwar V, Amidon GL, Levy RJ (1996) Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 13(12):1838–1845
Jung TK, Breitenbach W, Hungerer A, Hundt K-D, Kissel E (2001) Thomas Tetanus toxoid loaded nanoparticles from sulfobutylated poly (vinyl alcohol)-graft-poly (lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm Res 18(3):352–360
McClean S, Prosser E, Meehan E, O’Malley D, Clarke N, Ramtoola Z et al (1998) Binding and uptake of biodegradable poly-DL-lactide micro-and nanoparticles in intestinal epithelia. Eur J Pharm Sci 6(2):153–163
Prego C, Garcia M, Torres D, Alonso M (2005) Transmucosal macromolecular drug delivery. J Control Release 101(1–3):151–162
Thanou M, Verhoef J, Junginger H (2001) Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev 52(2):117–126
Mourya VK, Inamdar NN (2009) Trimethyl chitosan and its applications in drug delivery. J Mater Sci Mater Med 20:1057–1079
Beloqui A, des Rieux A, Préat V (2016) Mechanisms of transport of polymeric and lipidic nanoparticles across the intestinal barrier. Adv Drug Deliv Rev 106:242–255
Lopes MA, Abrahim BA, Cabral LM, Rodrigues CR, Seiça RMF, de Baptista Veiga FJ et al (2014) Intestinal absorption of insulin nanoparticles: contribution of M cells. Nanomed Nanotechnol Biol Med 10(6):1139–1151
Lai SK, Wang Y-Y, Hanes J (2009) Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61(2):158–171
Neutra MR (1998) V. Role of M cells in transepithelial transport of antigens and pathogens to the mucosal immune system. Am J Physiol Gastrointest Liver Physiol 274(5):G785–GG91
Pohlmeyer I, Jörns J, Schumacher U, Van Damme E, Peumans W, Pfüller U et al (2005) Lectin histochemical investigations of the distal gut of chicks with special emphasis on the follicle-associated epithelium. J Veterinary Med Ser A 52(3):138–146
Hathaway L, Kraehenbuhl J-P (2000) The role of M cells in mucosal immunity. Cell Mol Life Sci 57(2):323–332
Clark MA, Hirst BH, Jepson MA (2000) Lectin-mediated mucosal delivery of drugs and microparticles. Adv Drug Deliv Rev 43(2–3):207–223
Jepson MA, Clark M, Foster N, Mason CM, Bennett M, Simmons N et al (1996) Targeting to intestinal M cells. J Anat 189(Pt 3):507
Jepson MA, Mason CM, Clark MA, Simmons NL, Hirst BH (1995) Variations in lectin binding properties of intestinal M cells. J Drug Target 3(1):75–77
Clark M, Jepson MA, Simmons NL, Booth TA, Hirst BH (1993) Differential expression of lectin-binding sites defines mouse intestinal M-cells. J Histochem Cytochem 41(11):1679–1687
Giannasca PJ, Giannasca KT, Falk P, Gordon JI, Neutra MR (1994) Regional differences in glycoconjugates of intestinal M cells in mice: potential targets for mucosal vaccines. Am J Physiol Gastrointest Liver Physiol 267(6):G1108–G1G21
Gebert A, Posselt W (1997) Glycoconjugate expression defines the origin and differentiation pathway of intestinal M-cells. J Histochem Cytochem 45(10):1341–1350
Giannasca PJ, Giannasca KT, Leichtner AM, Neutra MR (1999) Human intestinal M cells display the sialyl Lewis A antigen. Infect Immun 67(2):946–953
Mantis NJ, Cheung MC, Chintalacharuvu KR, Rey J, Corthésy B, Neutra MR (2002) Selective adherence of IgA to murine Peyer’s patch M cells: evidence for a novel IgA receptor. J Immunol 169(4):1844–1851
Yoo M-K, Kang S-K, Choi J-H, Park I-K, Na H-S, Lee H-C et al (2010) Targeted delivery of chitosan nanoparticles to Peyer’s patch using M cell-homing peptide selected by phage display technique. Biomaterials 31(30):7738–7747
Tekade RK, Kumar PV, Jain NK (2008) Dendrimers in oncology: an expanding horizon. Chem Rev 109(1):49–87
Svenson S (2009) Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm 71(3):445–462
Dufes C, Uchegbu IF, Schätzlein AG (2005) Dendrimers in gene delivery. Adv Drug Deliv Rev 57(15):2177–2202
Joshi N, Grinstaff M (2008) Applications of dendrimers in tissue engineering. Curr Top Med Chem 8(14):1225–1236
Kobayashi H, Brechbiel MW (2004) Dendrimer-based nanosized MRI contrast agents. Curr Pharm Biotechnol 5(6):539–549
Sakthivel T, Toth I, Florence AT (1999) Distribution of a lipidic 2.5 nm diameter dendrimer carrier after oral administration. Int J Pharm 183(1):51–55
Wiwattanapatapee R, Carreño-Gómez B, Malik N, Duncan R (2000) Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? Pharm Res 17(8):991–998
Florence A, Sakthivel T, Toth I (2000) Oral uptake and translocation of a polylysine dendrimer with a lipid surface. J Control Release 65(1–2):253–259
Pantzar N, Lundin S, Wester L, Weström B (1994) Bidirectional small-intestinal permeability in the rat to some common marker molecules in vitro. Scand J Gastroenterol 29(8):703–709
Kaminskas LM, Boyd BJ, Porter CJ (2011) Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. Nanomedicine 6(6):1063–1084
D’emanuele A, Jevprasesphant R, Penny J, Attwood D (2004) The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release 95(3):447–453
Pisal DS, Yellepeddi VK, Kumar A, Kaushik RS, Hildreth MB, Guan X et al (2008) Permeability of surface-modified polyamidoamine (PAMAM) dendrimers across Caco-2 cell monolayers. Int J Pharm 350(1–2):113–121
Misumi S, Masuyama M, Takamune N, Nakayama D, Mitsumata R, Matsumoto H et al (2009) Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer. J Immunol 182(10):6061–6070
Jyothi VGB, Sireesha C, Manikiran SS, Ramarao N (2017) Microsphere as a novel drug delivery – a review. World J Pharm Res 6(6):378–396
Singh M, Hemant K, Ram M, Shivakumar H (2010) Microencapsulation: a promising technique for controlled drug delivery. Res Pharm Sci 5(2):65
Jani P, McCarthy D, Florence A (1992) Nanosphere and microsphere uptake via Peyer’s patches: observation of the rate of uptake in the rat after a single oral dose. Int J Pharm 86(2–3):239–246
Jung C, Hugot J-P, Barreau F (2010) Peyer’s patches: the immune sensors of the intestine. Int J Inflamm 2010:823710
Eldridge JH, Meulbroek JA, Staas JK, Tice TR, Gilley RM (1989) Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. In: Immunobiology of proteins and peptides V. Springer, Boston, pp 191–202
Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR (1990) Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer’s patches. J Control Release 11(1–3):205–214
Jenkins P, Howard K, Blackhall N, Thomas N, Davis S, O’Hagan D (1994) The quantitation of the absorption of microparticles into the intestinal lymph of Wistar rats. Int J Pharm 102(1–3):261–266
Jani P, Halbert G, Langridge J, Florence A (1989) The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 41(12):809–812
LeFevre M, Olivo R, Vanderhoff J, Joel D (1978) Accumulation of latex in Peyer’s patches and its subsequent appearance in villi and mesenteric lymph nodes. Proc Soc Exp Biol Med 159(2):298–302
LeFevre M, Boccio A, Joel D (1989) Intestinal uptake of fluorescent microspheres in young and aged mice. Proc Soc Exp Biol Med 190(1):23–27
Keljo DJ, Hamilton JR (1983) Quantitative determination of macromolecular transport rate across intestinal Peyer’s patches. Am J Physiol Gastrointest Liver Physiol 244(6):G637–GG44
New R, Littlewood G, Guard P, Browning I, Hotten P (1997) Intestinal delivery of calcitonin in pig. Int J Pharm 156(1):1–8
Chen Y, Li G, Huang J, Wang R, Liu H, Tang R (2009) Comparison of self-microemulsifying drug delivery system versus solid dispersion technology used in the improvement of dissolution rate and bioavailability of vinpocetine. Yao xue xue bao/Acta Pharm Sin 44(6):658–666
Mundada VP, Sawant KK (2018) Enhanced oral bioavailability and anticoagulant activity of dabigatran etexilate by self-micro emulsifying drug delivery system: systematic development, In vitro, Ex vivo and In vivo Evaluation. J Nanomed Nanotechnol 9(1):1–13
Li F, Hu R, Wang B, Gui Y, Cheng G, Gao S et al (2017) Self-microemulsifying drug delivery system for improving the bioavailability of huperzine A by lymphatic uptake. Acta Pharm Sin B 7(3):353–360
Sun M, Zhai X, Xue K, Hu L, Yang X, Li G et al (2011) Intestinal absorption and intestinal lymphatic transport of sirolimus from self-microemulsifying drug delivery systems assessed using the single-pass intestinal perfusion (SPIP) technique and a chylomicron flow blocking approach: linear correlation with oral bioavailabilities in rats. Eur J Pharm Sci 43(3):132–140
Bhalekar MR, Pokale R, Bandivadekar M, Madgukar A, Nagore P (2016) Self micro-emulsifying drug delivery system for lymphatic uptake of Darunavir. J Drug Discov Dev Deliv 3(2):1–7
Cho H, Jun-Hyuk K, Ngo L, Tran P, Lee Y (2016) Preparation and evaluation of solid-self-emulsifying drug delivery system containing paclitaxel for lymphatic delivery. J Nanomater 2016:1–14
Holm R, Porter CJ, Edwards GA, Müllertz A, Kristensen HG, Charman WN (2003) Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. Eur J Pharm Sci 20(1):91–97
Kiyasu J, Bloom B, Chaikoff I (1952) The portal transport of absorbed fatty acids. J Biol Chem 199(1):415–419
Prasad YR, Puthli S, Eaimtrakarn S, Ishida M, Yoshikawa Y, Shibata N et al (2003) Enhanced intestinal absorption of vancomycin with Labrasol and D-α-tocopheryl PEG 1000 succinate in rats. Int J Pharm 250(1):181–190
Wilkhu JS, McNeil SE, Anderson DE, Perrie Y (2014) Consideration of the efficacy of non-ionic vesicles in the targeted delivery of oral vaccines. Drug Deliv Transl Res 4(3):233–245
Simão AMS, Bolean M, Cury TAC, Stabeli RG, Itri R, Ciancaglini P (2015) Liposomal systems as carriers for bioactive compounds. Biophys Rev 7(4):391–397
Ling SS, Magosso E, Khan NA et al (2008) Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm 32(3):335–345
Tiantian Y, Wenji Z, Mingshuang S, Rui Y, Shuangshuang S, Yuling M et al (2014) Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting. Int J Pharm 471(1–2):245–257
Kaur CD, Nahar M, Jain NK (2008) Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target 16(10):798–805
Hirano K, Hunt CA, Strubbe A, MacGregor RD (1985) Lymphatic transport of liposome-encapsulated drugs following intraperitoneal administration–effect of lipid composition. Pharm Res 2(6):271–278
Parker R, Sieber S, Weinstein J (1981) Effect of liposome encapsulation of a fluorescent dye on its uptake by the lymphatics of the rat. Pharmacology 23(3):128–136
Parker R, Priester E, Sieber S (1982) Comparison of lymphatic uptake, metabolism, excretion, and biodistribution of free and liposome-entrapped [14C] cytosine beta-D-arabinofuranoside following intraperitoneal administration to rats. Drug Metab Dispos 10(1):40–46
Parker RJ, Hartman KD, Sieber SM (1981) Lymphatic absorption and tissue disposition of liposome-entrapped [14C] adriamycin following intraperitoneal administration to rats. Cancer Res 41(4):1311–1317
Jackson A (1981) Intramuscular absorption and regional lymphatic uptake of liposome-entrapped inulin. Drug Metab Dispos 9(6):535–540
Kaledin VI, Matienko NA, Nikolin VP, Gruntenko YV, Budker VG (1981) Intralymphatic administration of liposome-encapsulated drugs to mice: possibility for suppression of the growth of tumor metastases in the lymph nodes. J Natl Cancer Inst 66(5):881–887
Kaledin VI, Matienko NA, Nikolin VP, Gruntenko YV, Budker VG, Vakhrusheva TE (1982) Subcutaneously injected radiolabeled liposomes: transport to the lymph nodes in mice. J Natl Cancer Inst 69(1):67–71
Khato J, Del Campo A, Sieber S (1983) Carrier activity of sonicated small liposomes containing melphalan to regional lymph nodes of rats. Pharmacology 26(4):230–240
Visani G, Isidori A (2009) Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin’s lymphoma. Expert Rev Anticancer Ther 9:357–363
Pukanud P, Peungvicha P, Sarisuta N (2009) Development of mannosylated liposomes for bioadhesive oral drug delivery via M cells of Peyer’s patches. Drug Deliv 16(5):289–294
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Patel, R.P., Shah, P., Barve, K., Patel, N., Gandhi, J. (2019). Peyer’s Patch: Targeted Drug Delivery for Therapeutics Benefits. In: Misra, A., Shahiwala, A. (eds) Novel Drug Delivery Technologies. Springer, Singapore. https://doi.org/10.1007/978-981-13-3642-3_5
Download citation
DOI: https://doi.org/10.1007/978-981-13-3642-3_5
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-3641-6
Online ISBN: 978-981-13-3642-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)